Clopidogrel Tablet, Film Coated
Product Images NDC 71335-0080

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Clopidogrel (NDC 71335-0080). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Clopidogrel Fig1)

A horizontal error bar plot showing the effect of various proton pump inhibitors (PPIs) on the exposure to clopidogrel active metabolite AUC. The plot compares dexlansoprazole 60 mg, lansoprazole 30 mg, pantoprazole 80 mg, and omeprazole 80 mg relative to clopidogrel bisulfate administered alone, with change values on the x-axis ranging from 0.4 to 1.4.*

FDA Label Image

Figure 2: Cardiovascular Death, Myocardial Infarction, And Stroke In The Cure Study (Clopidogrel Fig2)

A line graph showing cumulative event rates of cardiovascular death, myocardial infarction, and stroke over 12 months of follow-up. Two lines compare Placebo (+ aspirin) and Clopidogrel Bisulfate (+ aspirin), illustrating lower event rates with Clopidogrel Bisulfate. The graph includes a p-value indicating statistical significance.*

FDA Label Image

Figure-3 (Clopidogrel Fig3)

A forest plot chart depicting hazard ratios and 95% confidence intervals comparing Clopidogrel Bisulfate and placebo in various subgroups. The subgroups include age, gender, race, elevated cardiac enzyme status, diabetes, previous myocardial infarction and stroke, use of Heparin/LMWH, Aspirin dosage, GPIIb/IIIa antagonist use, Beta-blocker, and ACE inhibitor therapy. The plot visually indicates whether Clopidogrel or placebo is favored across these subgroups with points and confidence intervals along the hazard ratio scale.*

FDA Label Image

Figure 4: Cumulative Event Rates For Death In The Commit Study (Clopidogrel Fig4)

A Kaplan-Meier curve showing the percentage of deaths occurring before discharge over 28 days since randomization. The graph compares Clopidogrel 75 mg tablets with placebo, indicating a 7% proportional risk reduction in deaths for Clopidogrel (7.5%) compared to placebo (8.1%). The x-axis represents days since randomization, and the y-axis shows the percentage of patients who died before discharge.*

FDA Label Image

Figure 5: Cumulative Event Rates For The Combined Endpoint Re-infarction, Stroke Or Death In The Commit Study (Clopidogrel Fig5)

A Kaplan-Meier curve comparing Clopidogrel versus placebo in percentages of patients with death, re-infarction, or stroke over 28 days since randomization. The graph indicates a lower event rate for Clopidogrel (9.2%) versus placebo (10.1%), with a 9% proportional risk reduction noted.*

FDA Label Image

Figure 6: Effects Of Adding Clopidogrel Bisulfate To Aspirin On The Combined Primary Endpoint Across Baseline And Concomitant Medication Subgroups For The Commit Study (Clopidogrel Fig6)

A forest plot chart showing odds ratios with 99% confidence intervals comparing Clopidogrel Bisulfate versus placebo across multiple subgroups such as gender, age at entry, hours since onset, systolic blood pressure, heart rate, and fibrinolytic agent given. The plot visually indicates whether each subgroup favors Clopidogrel Bisulfate or placebo based on the odds ratio scale from 0.6 to 1.3.*

FDA Label Image

Figure 7: Fatal Or Non-fatal Vascular Events In The Caprie Study (Clopidogrel Fig7)

A line graph depicting the cumulative event rate percentage of fatal or non-fatal vascular events over 36 months of follow-up, comparing Aspirin and Clopidogrel Bisulfate. The graph shows two lines with Aspirin having a slightly higher event rate than Clopidogrel Bisulfate, with a statistical significance value (P=0.045). The x-axis represents months of follow-up; the y-axis shows cumulative event rate in percentage.*

FDA Label Image

Figure 8: Hazard Ratio And 95% Ci By Baseline Subgroups In The Caprie Study (Clopidogrel Fig8)

A forest plot chart comparing the hazard ratios with 95% confidence intervals for Clopidogrel Bisulfate versus Aspirin across qualifying conditions: Stroke, MI, PAD, and Overall. The chart shows numerical data for each condition on sample size and event percentages for both drugs, illustrating relative risk favoring either Clopidogrel Bisulfate or Aspirin.*

FDA Label Image

Chemical Structure (Clopidogrel Str)

Chemical structure of Clopidogrel Bisulfate showing its molecular arrangement including a thiophene ring, a chlorophenyl group, and other functional groups consistent with the active ingredient clopidogrel bisulfate.*

FDA Label Image

Label Image (Lbl713350080)

Label for Clopidogrel 75 mg tablet, film coated, packaged by Bryant Ranch Prepack in Burbank, CA. The label compares the product to Plavix 75 mg tablets by Aurobindo Pharma Limited. It includes storage instructions to keep tightly closed and maintain at 20°-25°C (68°-77°F). The NDC on the label is 71335-0080-1 with a package count of 90 tablets.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.